TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15992789
Drug: PTCA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTCA therapy
Study: 15992789
Drug: Non-therapy patients
Normalized name: lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-therapy patients
Study: 10231223
Drug: Antioxidant therapy
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant therapy (N‐acetylcysteine, selenium, vitamins C and E) for 7 days
Study: 6363154
Drug: Cotrimazine (sulfadiazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimazine (sulfadiazine 900 mg + trimethoprim 300 mg)
Study: 6363154
Drug: Ampicillin 2
Normalized name: ampicillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 2 g daily
Study: 27266229
Drug: Plai cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plai cream (n = 70 patients)
Study: 22874106
Drug: Ferumoxytol (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferumoxytol (two 510 mg i.v. injections within 5 ± 3 days)
Study: 12598441
Drug: NSAID ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID ophthalmic solution (bromfenac sodium hydrate) co-administered twice daily for 2 weeks
Study: 12598441
Drug: Latanoprost ophthalmic
Normalized name: latanoprost ophthalmic
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost ophthalmic solution administered once daily
Study: 12598441
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of bromfenac sodium hydrate ophthalmic solution
Study: 12598441
Drug: Re-administration of
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-administration of bromfenac sodium ophthalmic solution
Study: 6347277
Drug: Tamoxifen and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen and No further therapy (both)
Study: 30475959
Drug: Higher-protein group
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-protein group (>0.80 g · kg‐1 · d‐1)
Study: 30475959
Drug: Lower-protein group
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-protein group (≤0.80 g · kg‐1 · d‐1)
Study: 26654738
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate solution (RLS)
Study: 21935814
Drug: Flunarizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (10 mg, 2 capsules of 5 mg each)
Study: 23222289
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 capsules)
Study: 17186724
Drug: Qianggan Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qianggan Capsule combined with Lamivudine
Study: 17186724
Drug: Qianggan Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qianggan Capsule alone
Study: 10875616
Drug: gp120 vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp120 vaccines
Study: 8864325
Drug: Reboxetine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine 0.5 mg, 1 mg, or 4 mg
Study: 8864325
Drug: Amitriptyline 25
Normalized name: amitriptyline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 25 mg with alcohol (0.6 mg kg‐1)
Study: 8864325
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with alcohol (0.6 mg kg‐1)
Study: 1497132
Drug: bupivacaine+buprenorphine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine+buprenorphine (0.3 mg)
Study: 6407433
Drug: Calcium inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium inhibitors
Study: 30236904
Drug: Home-based biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based biofeedback therapy (20 min self-training sessions twice per day using a self-inserted probe for visual feedback)
Study: 30236904
Drug: Office-based biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office-based biofeedback therapy (therapist-guided pelvic floor training for six sessions over 3 months)
Study: 24691901
Drug: Nitazoxanide 675
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide 675 mg
Study: 24691901
Drug: Nitazoxanide 2700
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide 2700 mg
Study: 25239216
Drug: Carbohydrate (CHO)
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO) supplementation (maltodextrin solution)
Study: 7758234
Drug: Octreotide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (100 micrograms subcutaneous injections, 3 injections over one day)
Study: 7758234
Drug: Placebo (octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (octreotide vehicle, 3 injections over one day)
Study: 6163281
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulphate 600 mg daily
Study: 30782701
Drug: Usual and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual and Customary Treatment (UCT)
Study: 24049109
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg dmLT
Study: 24049109
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg dmLT
Study: 24049109
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg dmLT
Study: 24049109
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg dmLT
Study: 19667281
Drug: Efavirenz at
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz at 600 mg/day plus stavudine‐lamivudine
Study: 17561956
Drug: Sustained-release carbamazepine
Normalized name: carbamazepine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release carbamazepine (CBZ)
Study: 10911490
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg) daily
Study: 10911490
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg) every 3 days
Study: 364260
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of acetylsalicylic acid
Study: 27294812
Drug: 12-step facilitation
Normalized name: STEP 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-step facilitation therapy
Study: 21499123
Drug: Low-Dose IFN‐α-2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Dose IFN‐α-2a treatment
Study: 16723584
Drug: Brecanavir (BCV)
Normalized name: Brecanavir
DrugBank: Brecanavir (DB04887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brecanavir (BCV) 300 mg coadministered with 100 mg ritonavir (RTV)
Study: 16723584
Drug: Brecanavir (BCV)
Normalized name: Brecanavir
DrugBank: Brecanavir (DB04887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brecanavir (BCV) (doses ranging from 25 mg to 800 mg)
Study: 6406459
Drug: Bupropion hydrochloride
Normalized name: Bupropion Hydrochloride
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion hydrochloride (100, 200, and 400 mg)
Study: 6406459
Drug: d‐amphetamine sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐amphetamine sulfate (15 and 30 mg)
Study: 3873175
Drug: Dexamethasone antenatal
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone antenatal therapy
Study: 31710096
Drug: School-based interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based interventions (prohibition of sugary snack consumption, teacher supervised daily brushing using fluoridated toothpaste, oral health education)
Study: 31710096
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control (tooth brushing and oral health education)
Study: 31710096
Drug: Negative control
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control (only oral health education)
Study: 30053283
Drug: Canola oil
Normalized name: Canola Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canola oil diet; 60 g of treatment oil per day for 4 weeks; increased cholesterol efflux capacity by 39% (P < 0.05) compared to baseline.
Study: 30053283
Drug: High oleic
Normalized name: High Oleic Sunflower Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High oleic acid-canola oil diet; 60 g of treatment oil per day for 4 weeks; increased cholesterol efflux capacity by 34% (P < 0.05) compared to baseline.
Study: 30053283
Drug: DHA-enriched high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-enriched high oleic acid-canola oil diet; 60 g of treatment oil per day for 4 weeks; increased cholesterol efflux capacity by 55% (P < 0.05) compared to baseline.
Study: 30053283
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil and safflower oil blend diet; 60 g of treatment oil per day for 4 weeks; increased cholesterol efflux capacity by 49% (P < 0.05) compared to baseline.
Study: 30053283
Drug: Flax oil
Normalized name: Flax oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flax oil and safflower oil blend diet; 60 g of treatment oil per day for 4 weeks; increased cholesterol efflux capacity by 51% (P < 0.05) compared to baseline.
Study: 18641036
Drug: Generic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic formulation of Triomune 40 (stavudine 40 mg, lamivudine 150 mg, nevirapine 200 mg)
Study: 18641036
Drug: Branded formulation
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded formulation of Triomune 40 (stavudine 40 mg, lamivudine 150 mg, nevirapine 200 mg)
Study: 18641036
Drug: Generic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic formulation of Triomune 40
Study: 18641036
Drug: Branded formulation
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded formulation of Triomune 40
Study: 10536549
Drug: morphine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine plus diclofenac 1 mg kg‐1
Study: 10536549
Drug: morphine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine plus paracetamol 15-20 mg kg‐1
Study: 10536549
Drug: morphine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine plus a combination of both diclofenac and paracetamol
Study: 31482947
Drug: Saltier bread
Normalized name: Eazi-Breed CIDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saltier bread samples (no specific dosage mentioned)
Study: 31482947
Drug: Bread with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bread with oregano seasoning (no specific dosage mentioned)
Study: 25744418
Drug: Dairy-consumption group
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy-consumption group (400 g/d for 24 wk)
Study: 19188391
Drug: Doripenem (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doripenem (500 mg every 8 hours)
Study: 19188391
Drug: Levofloxacin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (250 mg every 24 hours)
Study: 18221624
Drug: Treatment step
Normalized name: PYRITHIONE ZINC 2.14 mg in 1 mL TOPICAL CREAM [Australian Gold Metro 365 Medicated Leave-In Treatment Step 3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment step 1
Study: 18221624
Drug: Treatment step
Normalized name: PYRITHIONE ZINC 2.14 mg in 1 mL TOPICAL CREAM [Australian Gold Metro 365 Medicated Leave-In Treatment Step 3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment step 2
Study: 18221624
Drug: Treatment step
Normalized name: PYRITHIONE ZINC 2.14 mg in 1 mL TOPICAL CREAM [Australian Gold Metro 365 Medicated Leave-In Treatment Step 3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment step 3
Study: 18221624
Drug: Treatment step
Normalized name: PYRITHIONE ZINC 2.14 mg in 1 mL TOPICAL CREAM [Australian Gold Metro 365 Medicated Leave-In Treatment Step 3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment step 4
Study: 18221624
Drug: Increasing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing treatment steps
Study: 9139274
Drug: IL‐6 urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐6 urinary excretion in IDDM patients with albuminuria (mean = 7.43 +/‐ 8.29 pg/mg creatinine)
Study: 9139274
Drug: TGF‐beta urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGF‐beta urinary excretion in IDDM patients with albuminuria (mean = 42.0 +/‐ 30.0 pg/mg creatinine)
Study: 2409613
Drug: Heparin-DHE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-DHE
Study: 6662638
Drug: Injection in
Normalized name: Emend Injection Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection in the upper arm
Study: 6662638
Drug: Subcutaneous thrombin
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous thrombin administration
Study: 18663487
Drug: Intensive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive group training protocol (exercise therapy, back school, operant-conditioning principles)
Study: 16204716
Drug: SUV(100) normalized
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUV(100) normalized by serum glucose with a g-value of -0.5
Study: 16204716
Drug: SUV(100) normalized
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUV(100) normalized by serum glucose with a g-value of -0.5 in patients with extreme glucose values
Study: 10206443
Drug: TVP‐low‐cholesterol diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: TVP‐low‐cholesterol diet (17 to 30 mg/d)
Study: 10206443
Drug: Standard cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cholesterol diet (190 to 550 mg/d)
Study: 7639017
Drug: EcSf2a-2 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: EcSf2a-2 vaccine strain, administered as 4 doses of ca. 7 x 10(8) c.f.u. on days 0, 3, 14, and 17
Study: 7639017
Drug: EcSf2a-2 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: EcSf2a-2 vaccine strain
Study: 25223836
Drug: Selisistat 5-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selisistat 5-600 mg single dose
Study: 25223836
Drug: Selisistat 100-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selisistat 100-300 mg once daily for 7 days
Study: 21469386
Drug: Control (general
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (general therapy without HBO)
Study: 11223448
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 or 40 mg daily)
Study: 9364692
Drug: 6-12 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-12 micrograms intradermal (i.d.) inoculation in three or four divided doses (Groups A-F)
Study: 9364692
Drug: 4 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 micrograms intradermal (i.d.) inoculation in four doses
Study: 9364692
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group G) received three 10 micrograms intramuscular (i.m.) inoculations
Study: 7908838
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of sustained-release somatuline
Study: 7908838
Drug: Injections of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections of sustained-release somatuline at 2-week intervals over a 6-month period
Study: 27780197
Drug: Dextrose gel
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose gel
Study: 20721698
Drug: Bivalirudin (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin (high-dose and low-dose protocols)
Study: 20721698
Drug: Heparin (standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (standardized protocol)
Study: 15011419
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg hyperbaric bupivacaine
Study: 2007107
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg hyperbaric bupivacaine
Study: 10225782
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment by selective adsorption followed by intravenous IgG
Study: 8782169
Drug: Selective adsorption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective adsorption using a tryptophan-linked polyvinyl alcohol gel adsorbent
Study: 2825746
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg) inhalation in volunteers and patients
Study: 2825746
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (1 mg kg‐1) oral administration in healthy volunteers
Study: 2825746
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (0.2 microgram kg‐1 for 30 min) intravenous administration in healthy volunteers
Study: 2825746
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg) multiple dosing four times daily for 7 days in volunteers
Study: 2825746
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg) multiple dosing four times daily for 1, 6, and 12 months in patients
Study: 29029563
Drug: Single-session, transdiagnostic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-session, transdiagnostic preventive intervention based on the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Study: 24362411
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with metformin (1000 mg BID) and liraglutide (1.2 mg QD s.c.)
Study: 24362411
Drug: Liraglutide (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.2 mg QD s.c.)
Study: 24362411
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg BID)
Study: 12637459
Drug: Doxorubicin 50
Normalized name: DOXOrubicin 50 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 50 mg/m² plus docetaxel 75 mg/m² (AT)
Study: 15611510
Drug: Doxorubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² (AC)
Study: 8626853
Drug: Daily sc
Normalized name: Blackhead Eliminating Daily Scrub
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sc GH treatment at a dose of 0.2 or 0.3 IU/kg
Study: 24220224
Drug: Treadmill training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treadmill training (15 min) plus conventional therapy
Study: 15699836
Drug: rhIL-10 (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-10 (1, 10, or 25 microg/kg) administered 2 mins before lipopolysaccharide (4 ng/kg)
Study: 15699836
Drug: rhIL-10 (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-10 (1, 10, or 25 microg/kg) administered 2 hrs before lipopolysaccharide (4 ng/kg)
Study: 14664657
Drug: Levofloxacin 750mg
Normalized name: LEVOFLOXACIN 750MG TAB
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 750mg once daily for 7-14 days
Study: 14664657
Drug: Levofloxacin 500mg
Normalized name: LEVOFLOXACIN 500MG TAB
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 500mg once daily for 7-14 days
Study: 14664657
Drug: Levofloxacin 750mg
Normalized name: LEVOFLOXACIN 750MG TAB
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 750mg once daily for 5 days
Study: 14664657
Drug: Levofloxacin 500mg
Normalized name: LEVOFLOXACIN 500MG TAB
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 500mg once daily for 7 days
Study: 14664657
Drug: Levofloxacin 500mg
Normalized name: LEVOFLOXACIN 500MG TAB
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 500mg once daily for 10-14 days
Study: 14664657
Drug: Levofloxacin 500mg
Normalized name: LEVOFLOXACIN 500MG TAB
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 500mg once daily for 28 days
Study: 14664657
Drug: Levofloxacin 500mg
Normalized name: LEVOFLOXACIN 500MG TAB
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 500mg once daily for 7-10 days
Study: 24401765
Drug: Prochlorperazine 5
Normalized name: prochlorperazine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine 5 mg
Study: 11392068
Drug: Placebo (NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (NaCl 0.9% 4 mL)
Study: 8806903
Drug: BAY u
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY u 3405 (50 mg)
Study: 1634480
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg tablet twice daily
Study: 4067974
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of oxygen
Study: 10406187
Drug: AdoMet (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: AdoMet (1200 mg/day, orally)
Study: 7756795
Drug: Human surfactant
Normalized name: recombinant human surfactant protein D
DrugBank: Zelpultide alfa (DB18587)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human surfactant therapy
Study: 2256759
Drug: Chronic daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic daily treatment with octreotide acetate
Study: 375460
Drug: Levamisole treatment
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole treatment (3 days before operation and 3 days a fortnight thereafter)
Study: 17584349
Drug: Adherence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence therapy (8 weekly sessions)
Study: 15101598
Drug: Cemented implant‐supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cemented implant‐supported single‐tooth crown
Study: 15101598
Drug: Screw‐retained implant‐supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screw‐retained implant‐supported single‐tooth crown
Study: 11434356
Drug: L-arginine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine supplementation (0.1 g/kg body weight/day)